Everything below concerns Stenabolic. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-03-02. Numbers and descriptions here follow the published literature rather than marketing material.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
| Property | Value | Notes |
|---|---|---|
| Appearance | Off-white to pale yellow solid | Visual description varies with purity and source |
| Solubility | Soluble in DMSO and ethanol; poorly soluble in water | Organic stock solutions are common in research |
| Typical storage | -20 °C, desiccated, protected from light | Avoid repeated freeze-thaw cycles |
| Typical analytical method | LC-MS or HPLC-UV | Reference standards are needed for quantification |
| Molar mass | Approximately 437.9 g/mol | Calculated from the reported free-base formula |
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
RuBisCO is one of many enzymes in the Calvin cycle. When RuBisCO facilitates the attack of CO2 at the C2 carbon of RuBP and subsequent bond cleavage between the C3 and C2 carbon, 2 molecules of glycerate-3-phosphate are formed. The conversion involves these steps: enolisation, carboxylation, hydration, C-C bond cleavage, and protonation.
It was this achievement that earned him his first Nobel prize in Chemistry in 1958. This discovery was crucial to the later sequence hypothesis of Francis Crick for developing ideas of how DNA codes for proteins.
List of New York City Designated Landmarks in Manhattan from 14th to 59th Streets List of New York City parks List of New York City scenic landmarks National Register of Historic Places listings in Manhattan from 14th to 59th Streets
Pierre, et de Beatrix de Guine (1738 - English translation: Stories of the Earl of Oxford, of Milady of Herby, of Eustace of St. Peter, and of Beatrix of Guinea) La jeune Alcidiane (1733 - English translation: The Young Alcidiane) Les journées amusantes, dédiées au roi (1722 - English translation by Eliza Haywood: La Belle Assemblée published 1724–1734)
=== Temperature Modulated DSC === When performing Temperature Modulated DSC (TMDSC, MDSC), the underlying linear heating rate is superimposed by a sinusoidal temperature variation. The benefit of this procedure is the ability to separate overlapping DSC effects by calculating the reversing and the non-reversing signals. The reversing heat flow is related to the changes in specific heat capacity (→ glass transition) while the non-reversing heat flow corresponds to time-dependent phenomena such as curing, dehydration and relaxation.
Sources: en.wikipedia.org
Florey developed a detailed project plan and deployed eight graduate researchers on it, including Sanders, Medawar and Taylor. Florey performed delicate surgery on rabbits to examine the effects of lymphocyte deprivation. The project, not completed for many years, resulted in several papers and advances in the understanding of the immune system. Florey continued with his lysozyme project. Although the MRC had agreed to pay Roberts's salary, it baulked at providing money for a piece of apparatus that he required. Florey then turned to the Rockefeller Foundation for assistance, and was provided with US$1,250 (about £320)(equivalent to $29,000 in 2025). Florey and Maegraith harvested lysozyme from animals, and Roberts was able to purify it. Edward Abraham then managed to crystallize it in 1937. Chain and Epstein then studied it and determined that it was a polysaccharidase and, with Gardner's help, were able to determine its structure, and how it acted on polysaccharides. The lysozyme research was successful, but while it was lethal to micrococci, these bacteria are not usually pathogenic, and were of little concern to medicine.
All darmstadtium isotopes are extremely unstable and radioactive; in general, the heavier isotopes are more stable than the lighter. The most stable known darmstadtium isotope, 281Ds, is also the heaviest known darmstadtium isotope; it has a half-life of 14 seconds. The isotope 279Ds has a half-life of 0.18 seconds, while the unconfirmed 281mDs has a half-life of 0.9 seconds. The remaining isotopes and metastable states have half-lives between 1 microsecond and 70 milliseconds. Some unknown darmstadtium isotopes may have longer half-lives, however. Theoretical calculation in a quantum tunneling model reproduces the experimental alpha decay half-life data for the known darmstadtium isotopes. It also predicts that the undiscovered isotope 294Ds, which has a magic number of neutrons (184), would have an alpha decay half-life on the order of 311 years; exactly the same approach predicts a ~350-year alpha half-life for the non-magic 293Ds isotope, however.
Adropin is a protein encoded by the energy homeostasis-associated gene ENHO in humans and is highly conserved across mammals. The biological role of adropin was first described in mice by Andrew Butler's team. They identified it as a protein hormone (hepatokine) secreted from the liver, playing a role in obesity and energy homeostasis. The name "Adropin" is derived from the Latin words "aduro" (to set fire to) and "pinguis" (fat). Adropin is produced in various tissues, including the liver, brain, heart, and gastrointestinal tract. In animals, adropin regulates carbohydrate and lipid metabolism and influences endothelial function. Its expression in the liver is controlled by feeding status, macronutrient content, as well as by the biological clock. Liver adropin is upregulated by estrogen via the estrogen receptor alpha (ERα). In humans, lower levels of circulating adropin are linked to several medical conditions, including the metabolic syndrome, obesity, and inflammatory bowel disease. and inflammatory bowel disease. The brain exhibits the highest levels of adropin expression, In the brain, adropin has been shown to have a potential protective role against neurological disease, where it may play a protective role against neurological diseases, brain aging, cognitive decline, and acute ischemia. as well as following acute ischemia. The orphan G protein-coupled receptor GPR19 has been proposed as a receptor for adropin.
=== Functions === As per Art. 320, it shall be the duty of the Union Public Service Commission to conduct examinations for appointments to the services of the Union. It shall also assist two or more states, if requested so, in framing and operating schemes of joint recruitment for any services.
Sources: en.wikipedia.org
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.
The compound is generally handled as light-sensitive and stored cold and dry. Stability in solution depends on solvent, concentration, and storage time. Specific degradation rates are not fully standardized.
Limited water solubility affects formulation for cell and animal studies. Organic co-solvents are often used to dissolve it. Precipitation can confound assay results if not controlled.
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.